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Edited by Richard MaraisAbstract PKCfII is a rapidly degraded variant of PKCf that
suppresses epithelial cell polarisation. It is shown here that
PKCfII is a target for the E3 ligase and tumour suppressor
Von Hippel-Lindau protein (pVHL). Deletion studies demon-
strate that the C-terminal region is required for the pVHL and
proteasome dependent turnover of PKCfII, however it is the
N-terminal PB1 domain of PKCfII that is required for pVHL
complex formation. Reciprocal deletion studies deﬁne the pVHL
eﬀector domain as the dominant PKCfII binding site. The results
indicate that pVHL recruits PKCfII via its PB1 domain and
causes ubiquitination and degradation via the distal C-terminus
of PKCfII.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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PB1 domain1. Introduction
The turnover of key regulators has become increasingly
recognised as an important regulatory device. Thus for exam-
ple the cyclical behaviour of cyclins during progression
through the cell cycle is determined by a complex set of events
that determine the moments of their destruction in line with
the completion of speciﬁc cell-cycle associated tasks, such as
chromosome duplication, and segregation (reviewed [1]). Such
proteolytic processes are involved not only in sequential cas-
cades typiﬁed by the cell cycle, but also in the acute intracellu-
lar relay of signals. This is well established for the activation of
NFjB where degradation of the inhibitory IjB is required for
activation [2–4] and also for the induction of hypoxia inducible
factor 1a (Hif1a) which is controlled through protein turnover
[5].Abbreviations: PKC, Protein kinase C; pVHL, Von Hippel-Lindau
protein; Hif1a, Hypoxia inducible factor 1a
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doi:10.1016/j.febslet.2007.02.059The mammalian aPKC family belongs to the large family of
AGC serine/threonine kinase and is distinguished from the two
other subfamilies of protein kinase C (PKC) by its lack of acti-
vation by phorbol esters [6]. There are two full length aPKCs,
PKCf and PKCi, and in addition to these two other isoforms
of PKCf have been identiﬁed and have been named PKMf and
PKCfII [7,8]. PKMf is synthesised following transcription ini-
tiation of the PKCf gene from a brain-speciﬁc promoter lo-
cated in an intron and results in the expression of PKCf
catalytic fragment that is constitutively activate [9]. PKCfII
is a rapidly degraded variant that comprises an aPKCf regula-
tory domain without an associated kinase domain. PKCfII has
been shown to interact with Par6 and to be an endogenous
inhibitor of tight junction formation playing a regulatory role
in the development of cell polarity [7].
The turnover of PKCfII may be mediated by the ubiquitin-
proteasome system; ubiquitination of activated PKCf in HeLa
cells has been reported [10]. Interestingly, the E3 ligase pVHL
(Von Hippel-Lindau tumour suppressor gene product) has
been shown to support poly-ubiquitination of the related
PKCi and is to date the only described ubiquitin-ligase show-
ing speciﬁcity for a member of PKC family [11]. pVHL inter-
acts with the regulatory domain of PKCi [12], suggesting that
PKCfII may interact with pVHL in the same way. By such a
mechanism pVHL may be responsible for controlling PKCfII
turnover and thereby would have an important function in reg-
ulating cell polarity. To explore this predicted function of
pVHL we have tested whether pVHL can regulate PKCfII
expression levels. Here we deﬁne PKCfII as a target for pVHL
dependent degradation.2. Material and methods
2.1. Antibodies and chemicals
Mouse anti-Hif1a and rabbit anti-GFP antibodies were purchased
from BD Transduction Laboratories and BD Clontech (AV peptide
polyclonal) respectively. Mouse myc (9E10) and GFP (3E1) antibodies
were obtained from the CRUK monoclonal facility. Rabbit anti-Flag
antibody was obtained from Sigma Aldrich. Horseradish peroxidase-
conjugated antibodies were obtained from Amersham. Cy3-conjugated
anti-rabbit and anti-mouse were from Dako. MG132 was obtained
from Calbiochem.2.2. Cell culture and transfections
COS7, 293T and MDCK were maintained in DMEM containing
10% FBS, penicillin/streptomycin. All the cells were cultivated at
37 C, 5% CO2. Cells were transfected with Lipofectamine 2000 (Invit-
rogen) following the manufacturer’s instructions.blished by Elsevier B.V. All rights reserved.
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pVHL–GFP constructs, pcDNA3 myc-PKCfII full length (FL 376
amino acid) and GFP–PKCf A119/E were described previously
[7,13]. pcDNA3 Hif1a was provided by Dr. N. Masson and Prof. P.
Ratcliﬀe (IMM, Oxford). The 14.3.3b cDNA was kindly provided by
Prof. A. Aitken (Edinburgh). Flag-Par6C constructs were generously
provided by Prof. T. Pawson (Toronto). Myc-PKCfII truncated con-
structs, 294, 269 and 236 were obtained by digesting pcDNA3 Myc-
PKCfII with EcoRV (294), XcmI (269) and ClaI (236) and the Myc-
PKCfII PB1 domain construct was made by PCR using the oligonucle-
otides 5 0-CCCAAGCTTATGCCGGAGCAGAAGCTGATATCC-
GAGGAGGACCTGGCCATGCCCAGCAGGACGGACCCCA-3 0
(HindIII) and 5 0-CCGCTCGAGTCATGGGATGCTTGGGAAAA-
CATGAATG-3 0 (XhoI) as forward and reverse primers respectively.
The PCR product was digested with HindIII–XhoI and was ligated
into the pcDNA3.1 Hygro (Invitrogen) digested by the same restriction
enzymes.
2.4. Co-immunoprecipitation experiments
After 24 h of transfection, COS7 cells were washed once with phos-
phate buﬀer saline (PBS), harvested in 500 ll of lysis buﬀer (50 mM
Tris–HCl pH 7.5, 150 mM NaCl, 0.5% NP40, 20 mM NaF, 2 mMFig. 1. PKCfII is constitutively degraded by the proteasome. (a) COS7 and
and pEGFP empty vector and MDCK cells were transfected with pcDNA3 m
or not with 16 lM MG132 for 6 h. Cell lysates were subjected to Western blo
transfected with pcDNA3 myc-PKCfII FL and C-terminus truncated fragm
treated or not with 16 lM MG132 for 6 h. Cell lysates were subjected to We
western blots representing myc-PKCfII FL or the truncation mutants (D294,
This data derives from three independent experiments and shows means andEDTA, 2 mM EGTA, 2 mM Orthovanadate, Proteasome inhibitors
Complete Tablet (Amersham)). After 30 min of incubation on ice
and centrifugation at 10,000 rpm for 10 min the supernatants were
subjected to immunoprecipitation (IP) for 2 h at 4 C, with rabbit
anti-GFP (0.5 ll per IP) and Protein A Sepharose or mouse anti-
myc (10 ll per IP). The beads were washed ﬁve times with 1 ml of lysis
buﬀer and the ﬁnal bead pellets were resuspended in 40 ll of 2X sample
buﬀer, boiled and resolved by SDS–PAGE and then proteins detected
by Western blotting. Immunoreactivity was analyzed by chemilumines-
cence using ECL (Amersham).
2.5. Immunoﬂuorescence
COS7 were transfected with YFP–VHL and myc-PKCfII in cover-
slips. After 24 h of transfection the coverslips were washed once with
PBS, ﬁxed for 10 min with 2% PFA in PBS and then washed three times
with PBS. The cells were then permeabilised and blocked with 0.1%
Triton X100, 1% bovine serum albumin (BSA) in PBS. After 20 min
of permeabilisation the coverslips were incubated with a primary anti-
body mouse anti-myc (1/250 in PBS 1% BSA) for 1 h, washed three
times with PBS and then incubated for 45 min with Cy3-conjugated sec-
ondary antibodies (1/500). Finally, coverslips were washed three times
with PBS and once with distilled water before mounting in slides with293T were co-transfected with pcDNA3 myc-PKCfII full length (FL)
yc-PKCfII FL alone. One day after transfection the cells were treated
t analysis using anti-myc and anti-GFP antibodies. (b) 293T cells were
ents (D294, D269 and D236). The day after transfection the cells were
stern blot analysis using anti-myc antibody. Densitometric analysis of
D269 and D236) protein levels are aligned with the experiment shown.
S.D.; **P < 0.005.
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microscope (LSM 510, Carl Zeis Inc.) equipped with Krypton/Argon
lasers and with 63·/1.4 Plan-APOCHROMAT oil-immersion objective.
Double-labeling images (1024 · 1024 pixels) were analyzed in sequen-
tial scanning mode by exciting YFP at 488 nm and Cy3 at 543 nm. Each
image corresponds to an equatorial section of the cell.Fig. 2. pVHL mediates PKCfII degradation. (a) 293T cells were co-
transfected with pcDNA3 myc-PKCfII FL and pVHL–EGFP con-
structs (wild type (WT) and mutants Y98H, C162W and R167W). Cell
lysates were subjected to Western blot analysis using anti-myc and
anti-GFP antibodies. (b) Densitometric analysis of western blots
representing myc-PKCfII FL protein levels. Each bar represents three
independent experiments. Ns – not signiﬁcant, *P > 0.05; P < 0.05
(Student’s t-test). (c) 293T cells were co-transfected with pVHL–EGFP
constructs and Hif1a or myc-PKCfII FL or myc-14.3.3 or GFP–
PKCfA119/E. Cell lysates were subjected to Western blot analysis
using anti-Hif1a or anti-myc or anti-GFP antibodies. (d) 293T cells
were transfected with pcDNA3 myc-PKCfII FL or C-terminal
truncation fragments (294, 269 and 236) with or without pVHL–
GFP WT or R167W as indicated. Cell lysates were subjected to
Western blot analysis using anti-myc antibody.3. Results and discussion
3.1. PKCfII is constitutively degraded by the proteasome
Previous studies establishing PKCfII as a regulatory device
for polarisation indicated that the protein is subject to rapid
turnover [7]. To test the possible role of the proteasome, diﬀer-
ent cell lines (COS7, 293T and MDCK) were transfected with a
myc-PKCfII construct and cultures treated with or without the
proteasome inhibitor MG132 (Fig. 1a). Interestingly, the treat-
ment of COS7, 293T or MDCK cell lines with MG132 signif-
icantly increases the expression of myc-PKCfII. This was not a
pleiotropic eﬀect since co-transfection with a control vector
expressing GFP was unaﬀected by MG132 (Fig. 1 upper
panel). This result suggests that PKCfII is constitutively
degraded by the ubiquitin-proteasome system.
PKCfII deletion mutants were tested to investigate what was
required for the engagement of this proteasome sensitive path-
way. As illustrated in Fig. 1b and quantiﬁed in the lower panel,
PKCfII itself is stabilised byMG132 in 293T cells. The 294 mu-
tant displayed modest but not signiﬁcant stabilisation, while
further deletions (269, 236) were intrinsically expressed more
eﬃciently and were also insensitive to MG132. Hence eﬀective
engagement with this degradative machinery requires the C-ter-
minal region of PKCfII spanning amino acids 269–376.
3.2. pVHL mediates PKCfII degradation
Typically proteins degraded through the proteasome are tar-
geted by E3 ligases. The related translation product PKCf has
been shown to interact with the E3 ubiquitin ligase pVHL [12].
This has been reported to be involved speciﬁcally in the degra-
dation of the T410 phosphorylated aPKC [14], a kinase do-
main phosphorylation site absent from PKCfII. To assess
whether pVHL is involved in PKCfII degradation, WT and
mutant forms of pVHL were co-expressed with myc-PKCfII
in 293T cells and expression monitored. WTpVHL had no
overt eﬀect on PKCfII expression; similarly, the Y98H mutant
has no inﬂuence. However the C162W and R167W pVHL mu-
tants both stabilised PKCfII to the levels seen in the presence
of MG132 (Fig. 2a and quantiﬁed in Fig. 2b). These two mu-
tants are not able to bind the Cul2 complex (for review see [15])
and hence have dominant eﬀects on pVHL targeted proteins,
since they can interact but fail to induce ubiquitination.
To establish the speciﬁcity and function of the pVHL mu-
tant proteins, the endogenous levels of Hif1a were assessed
along with a myc-14.3.3b control. As predicted from prior
studies, the over-expressed Y98H, C162W and R167W mu-
tants all protect Hif1a leading to its accumulation when com-
pared to the expression of WTpVHL. The myc-14.3.3b control
was not inﬂuenced by any of the mutant or WT pVHL pro-
teins (Fig. 2c).
In order to compare the eﬀects of pVHL and those of
MG132, WT or the R167W mutant of pVHL were co-ex-
pressed with PKCfII deletion mutants (Fig. 2d). The R167W
mutant increased PKCfII expression 4.5 ± 1.6-fold (compared
to 4.6 ± 1.1-fold for MG132; see above). Furthermore, essen-tially the same pattern of stabilisation is observed for the
R167WpVHL mutant with PKCfII deletions. The WTpVHL
had no eﬀect. Thus the dominant eﬀect of R167WpVHL phe-
nocopies treatment with MG132, indicating that pVHL is key
to engaging PKCfII on the proteasomal and degradative path-
way.
3.3. The PB1 domain of PKCfII is required for interaction with
pVHL
Although deletion of the C-terminal 93 amino acids of
PKCfII is suﬃcient to stabilise the protein, it is not clear
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tion or for the subsequent ubiquitination and degradation of
PKCfII. This was established by investigating directly the inter-
action of pVHL and PKCfII. In initial studies the unusual
localisation of the YFP-pVHL fusion protein was employed
to determine interaction of pVHL and PKCfII in intact cells
[13]. On expression of myc-PKCfII the protein typically accu-
mulates in the nucleus as described previously (Fig. 3a; [7]).
However on co-expression with YFP-pVHL, PKCfII is re-
cruited to the cytosolic YFP-pVHL positive structures. This is
consistent with an interaction of these two proteins in cells.
The same co-localisation was observed for the deletion mutants
as illustrated for the 294 and 236 mutants (Fig. 3a, lower pan-Fig. 3. The PB1 domain of PKCfII is required for interaction with pVHL. (a
PKCfII D294 or D236 mutants with or without pYFP–VHL WT as indicated
myc antibody. Localisation of myc-PKCfII protein and mutants is in red and
illustrated by the arrows in each panel. (b) Schematic representations of myc-
PKCfII FL or C-terminal truncation fragments (294, 269 and 236) and VHL–
myc antibody and immunoprecipitated materials were analysed by wester
transfected with myc-PKCfII PB1 and with Flag-Par6C or VHL–GFP. C
antibody and immunoprecipitated materials were analysed by Western blotels). A direct biochemical assessment of interaction was carried
out through co-immunoprecipitation, employing myc-PKCfII
and the C-terminal deletion series described above (Fig. 3b).
It was established that theWTprotein and all three deletionmu-
tants can be recovered in PKCfII immunocomplexes (Fig. 3c).
Further deletion deﬁned the PB1 domain as that interacting
with pVHL (Fig. 3d). This domain has been shown to interact
with Par6 [16], which serves here as a control for the PB1 do-
main interaction. Notably, when pVHL is present, the recov-
ery of Par6c in the PKCfII immuno-complex is substantially
reduced indicative of mutual exclusivity of these two PB1 do-
main interacting partners. It has not been possible to formally
establish the absence of pVHL in a Par6C–PKCfII complex) COS7 cells were transfected with pcDNA3 myc-PKCfII FL, the myc-
. Fixed cells were subjected to immunoﬂuorescence labeling with anti-
that of YFP-pVHL protein is in green. Colocalisation of the proteins is
PKCfII constructs. (c) COS7 cells were transfected with pcDNA3 myc-
GFP. Cell lysates were subjected to immunoprecipitation using an anti-
n blot with anti-myc and anti-GFP antibodies. (d) COS7 cells were
ell lysates were subjected to immunoprecipitation using an anti-myc
with anti-myc, anti-Flag and anti-GFP antibodies.
Fig. 4. The N-terminal b-domain of pVHL is required for PKCfII interaction. (a) Schematic representation of pVHL constructs. (b) COS7 cells were
transfected with myc-PKCfII 236 and VHL–GFP constructs. Cell lysates were subjected to immunoprecipitation with an anti-GFP antibody and
immunoprecipitated materials were analysed by western blot with anti-myc and anti-GFP antibodies.
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dently of PKCfII (data not shown).3.4. The N-terminal b-domain of pVHL is required for PKCfII
interaction
To deﬁne the site(s) of interaction of PKCfII on pVHL, a ser-
ies of deletions and mutations were analysed, speciﬁcally those
associated with pVHL subclass mutations (Fig. 4a). Co-immu-
noprecipitations of these were carried out using the myc-
PKCfII 236 construct, which is readily expressed in COS7 cells.
Myc-PKCfII 236 was found to interact with WT pVHL as well
as the two mutants of the pVHL a domain (C162W and
R167W), which stabilised myc-PKCfII as shown above. This
result suggests that the stabilisation of PKCfII observed with
the co-expression of these two mutants of pVHL in 293T cells
is indeed mediated by their dominant-negative eﬀects over
endogenous pVHL, consequent to their inability to interact
with the VCB–Cul2 complex. Interestingly the mutant Y98H
pVHL, which does not stabilise PKCfII, interacts only weakly
with myc-PKCfII 236. A similar result is observed with the
deletion construct D87–130 of pVHL and the truncation mu-
tant of pVHL, 122 (Fig. 4b). Finally, pVHL truncated to 113
does not interact with PKCfII suggesting that the domain of
interaction of PKCfII in pVHL is located between residues
87 and 122 of pVHL as previously reported for PKCf [12].3.5. Concluding remarks
The evidence presented here demonstrates that PKCfII is
degraded in part via a proteasome depedent pathway. It isfurther shown that this pathway involves the E3 ligase pVHL
with which PKCfII interacts in cells and in co-immunoprecipi-
tations. The domains involved in the kinase-ligase interaction
have been mapped to the PKCfII PB1 domain and the previ-
ously deﬁned pVHL eﬀector binding domain [12]. Interest-
ingly, the PB1 domain of PKCfII does not display
proteasome sensitivity in cells, a property that in fact maps
to the C-terminus of PKCfII. Hence the recruitment and the
ability of pVHL to determine PKCfII turnover are situated
at distinct ends of the protein.
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